AlphaStocks

INVA vs VAL

As of Sep 21, 2026, Innoviva (INVA) scores 4.8/10 and Valaris (VAL) 4.6/10 on AlphaStocks' five-model composite, so INVA scores higher.

INVA

Innoviva, Inc.

4.8

Weak

$21.13

VAL

Valaris Ltd

4.6

Weak

$83.77

INVA vs VAL: Which is the Better Investment?

Innoviva, Inc. (INVA) scores 4.8/10 while Valaris Ltd (VAL) scores 4.6/10 on AlphaStocks' composite model. Innoviva, Inc. has the higher composite rating of Weak. On a P/E basis, Valaris Ltd trades at 6.0x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricINVAVAL
Scores & Fundamentals
Composite Score4.8/104.6/10
RatingWeakWeak
Price$21.13$83.77
P/E Ratio6.66.0
ROE24.8%35.0%
Market Cap$2B$6B
Fair Value
Dividend Yield
Sector Rank#118 of 168#37 of 80
Model Verdicts
PiotroskiAttractiveStrong
BuffettAttractiveAttractive
GrahamAttractiveNeutral
LynchStrongNeutral
GreenblattStrongAttractive
View full INVAanalysis →View full VALanalysis →

Related comparisons

Compare any two stocks →

INVA vs VAL: Which Stock Scores Higher?

Innoviva, Inc. (INVA) is in the Health Care sector; Valaris Ltd (VAL) is in Energy. INVA currently leads with a composite score of 4.8/10 (Weak) compared to VAL's 4.6/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer